NEW DELHI: Merck and Ridgeback Biotherapeutics, LP on Saturday announced preliminary results from Ridgebacks Phase 2a randomized, double-blind, placebo-controlled trial to evaluate the safety, tolerability, and efficacy to eliminate SARS-CoV-2 viral RNA of Molnupiravir, an investigational oral antiviral agent.